MWNA
TBPH icon

Marshall Wace North America’s Theravance Biopharma TBPH Stock Holding History

Marshall Wace North America’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-350
Closed -$1.05M – 1492
2017
Q2 		$1.05M Buy
+350
New +$13.5K 0.01% 924

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Marshall Wace North America's TBPH Position: Q1 2019 in Review

Marshall Wace North America sold out of Theravance Biopharma (TBPH) in Q1 2019, closing a stake of 1,215 shares — an estimated $31K sold.

Marshall Wace North America first reported a position in TBPH in Q1 2017 and held it in 3 quarters. The position peaked at $21.9M in Q1 2017. 104 funds tracked by Wall St. Rank hold TBPH as of Q1 2019.

  • Marshall Wace North America reported no remaining Theravance Biopharma position as of Q1 2019 after selling out during the quarter.
  • Marshall Wace North America sold 1,215 Theravance Biopharma shares in Q1 2019, an estimated $31K.
  • Marshall Wace North America first reported a position in Theravance Biopharma in Q1 2017 and held it in 3 quarters.
  • Marshall Wace North America's Theravance Biopharma position peaked at $21.9M in Q1 2017.
  • 104 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.